Advertisement
News
Advertisement

Cellectis Publishes Its Financial Statement for the First Half of 2010

Fri, 10/15/2010 - 1:31am
Bio-Medicine.Org

PARIS, Oct. 15 /PRNewswire-FirstCall/ -- Cellectis (Alternext: ALCLS), the French genome engineering specialist, today published its consolidated financial statement for the half-year ending June 30, 2010: revenues increased 25% over H1 2009, expenditure increased 50% and the company ended the period with euro 38 million in cash reserves.

During the first half of 2010, Cellectis entered into a number of important new agreements (with BASF Plant Science, Boehringer Ingelheim), published data in a peer-reviewed journal on the therapeutic potential of meganucleases in Duchenne muscular dystrophy and launched Cellectis plant sciences. Cellectis was also granted the INPI National Innovation Award for its intellectual property strategy. In addition, Cellectis' research and production tools subsidiary, Cellectis bioresearch, entered into a development and commercial manufacturing agreement with Lonza that establishes a presence for Cellectis in the bioproduction market.

"The figures for this half year reflect our growth strategy," said Andre Choulika, CEO at Cellectis. "Cellectis' staff has doubled in a year and comprises 130 people today, in all entities, compared to 65 in July 2009. This has allowed us to strengthen our position, in all aspects of our business, with highly competent and committed people."

"The capital increase that was made in October 2009 allows us to finance this rapid growth and support our ambitious external growth strategy," added Marc Le Bozec, CFO at Cellectis.

The slide show presenting the half-year results in details is available on http://www.cellectis.com/investors/accounts-and-reports Simplified Income Statement – Financial items are presented according to IFRSFigures in thousands of euros

2010

first 6 months2009

first  6 monthsSales

6 2505 020Other revenue

'/>"/>

SOURCE

Topics

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading